繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

KKR房地产金融信托非GAAP每股收益为-0.04美元,击败0.04美元

2025-07-23 04:23

  • KKR Real Estate Finance Trust press release (NYSE:KREF): Q2 Non-GAAP EPS of -$0.04 beats by $0.04.
  • Second Quarter 2025 Highlights
  • $756.7 million liquidity position, including $107.7 million of cash and $620.0 million of undrawn capacity on our corporate revolving credit agreement as of June 30, 2025 • Originated and funded $210.7 million and $210.4 million, respectively, relating to two floating-rate loans, with a weighted average appraised loan-to-value ratio ("LTV")(1) and coupon of 71% and S+2.4%, respectively; and funded $19.8 million in loan principal for existing loans • Received $450.1 million in loan repayments • Current loan portfolio of $5.8 billion: • 99% floating rate with a weighted average unlevered all-in yield(2) of 7.6% as of June 30, 2025 • Multifamily and industrial assets represent 62% of the loan portfolio • Weighted average LTV of 66% • Collected 99.9% of interest payments due on the loan portfolio • Average risk rating of the loan portfolio was 3.1, weighted by outstanding principal amount • Diversified financing sources totaling $8.2 billion with $3.2 billion of undrawn capacity: • 78% of secured financing is fully non-mark-to-market and the remaining balance is mark-to-credit only • No final facility maturities until 2026 and no corporate debt due until 2030 • Entered into a new $100.0 million term lending agreement, with the ability to upsize, which provides match-term financing on a non-mark-to-market basis • Resolved a risk-rated 5 loan by taking title to a multifamily property in West Hollywood, CA, resulting in a realized loss of $20.4 million. • Sold certain real estate owned assets, including a parking garage in Philadelphia, PA and a retail/redevelopment parcel in Portland, OR for a combined gain of $1.2 million • Invested $9 million in CMBS B-Pieces • Repurchased and retired 2,170,904 shares at an average price per share of $9.21 for a total of $20.0 million • Common book value of $912.3 million, or $13.84 per share, as of June 30, 2025, inclusive of a CECL allowance of $173.9 million, or ($2.64) per share. The CECL allowance increased by of $49.8 million, or ($0.74) per share, for the three months ended June 30, 2025 primarily due to additional reserves for watchlist loans in the office and life science sectors.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。